Bioline RX Ltd Sponsored ADR Stock

$0.27

2.30% yesterday

Nasdaq, Nov 25, 10:16 pm CET

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Bioline RX Ltd Sponsored ADR Stock price

$0.27

-2.43 89.94% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

-0.01 2.30%

ISIN

US09071M1062

Symbol

BLRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$22.85m
Enterprise Value	$23.29m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	1.06
P/S ratio (TTM) P/S ratio	1.04
P/B ratio (TTM) P/B ratio	1.55
Revenue (TTM) Revenue	$21.99m
EBIT (operating result TTM) EBIT	$-27.85m
Free Cash Flow (TTM) Free Cash Flow	$-30.35m
Cash position	$29.17m
EPS (TTM) EPS	$-0.27
P/E forward	negative
P/S forward	1.04
EV/Sales forward	1.06
Short interest	1.33%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Bioline RX Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Bioline RX Ltd Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Bioline RX Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	22 22	- 100%
- Direct Costs	7.52 7.52	764% 764% 34%
Gross Profit	14 14	1,763% 1,763% 66%
- Selling and Administrative Expenses	29 29	16% 16% 132%
- Research and Development Expense	10 10	19% 19% 47%
EBITDA	-25 -25	36% 36% -113%
- Depreciation and Amortization	2.92 2.92	236% 236% 13%
EBIT (Operating Income) EBIT	-28 -28	30% 30% -127%
Net Profit	-20 -20	62% 62% -91%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bioline RX Ltd Sponsored ADR Stock News

Neutral

Seeking Alpha

●

about 21 hours ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright Justin Walsh - Jones Trading John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

Neutral

PRNewsWire

●

5 days ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC – – BioLineRx received $9 million equity investment from certain funds managed by Hig...

Neutral

PRNewsWire

●

6 days ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.

More Bioline RX Ltd Sponsored ADR News

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Head office	Israel
CEO	Philip Serlin
Employees	38
Founded	2003
Website	www.biolinerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now